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1. Introduction 
Evidences related to the fact that there is a immunological functional disorder in autism are 
gradually increasing. Since immunological mechanisms play a role in the neuronal cell 
migration, axonal development and formation of synapses, it is mentioned that there is an 
immune - mediated inflammatory period exists (Bradstreet et al. 2007).  
Central nervous system and immune system are systems which are in interaction with each 
other and which are complex and highly developed (Ashwood and Water 2004). Immune 
cells and molecules play an important role in forming the brain functions by affecting the 
cognitive and emotional processes. These molecules have various effects such as infection, 
inflammation and injury on neural tissues, the modulation of central nervous system 
response and systematic response. It is indicated that proinflammatory cytokines such as 
interleukin (IL) – 1, IL -6, IL – 12, interferon (IFN) gamma and tumor necrosis factor (TNF)- 
alpha in particular directly affect the neural function and development by playing a role in 
the neurodevelopmental process. Applying the cytokines such as IFN – alpha, IL – 2, TNF–
alpha at therapeutical doses lead to the symptoms such as depression, sleep disorder, 
defects in cognitive functions, motivational change and decline in behavior of making 
research. It is reported that cytokines applied systematically may lead to increase in 
hypothalamus, hippocampus and nucleus accumbance and in noradrenergic, dopaminergic 
and serotenergic metabolism, and it may change the synaptic plasticity and therefore may 
affect the memory and learning processes (Ashwood et al. 2006). Findings which states that 
response of maternal immune to the infection, affect the fetal brain development through 
the increase in the cytokine level on circulation and which are collected from animal models 
support the role of immune system in the etiology of autism (Yamashita et al. 2003, 
Patterson 2002). It is mentioned that there is “abnormal” immune findings exists in 15 – 60 % 
of the autistic children (Pardo et al 2005). 
Two basic immune fuctional disorders in autism are associated with immune formation that 
includes autoimmunity and proinflammatory cytokines. The decline in the number of the 
CD4 lymphocyte numbers, the change of balance of T helper cell type 1(Th1)/ T helper cell 
type 2 (Th2) in the direction of Th2 and the response corruption of Th1 (corruption in cell - 
mediated immunity), the decline in the T lymphocyte response against mitogens, the decline 
in the natural killer’s functions and corruption shown by declined IgA level in humoral 
immunity are among immune system abnormalities indicated in autism (Cohly and Panja 
2005, Careaga et al. 2010).  
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It is put forward that infectious agents such as lead and measles virus are two basic 
environmental triggers and the environmental exposure to the lead affects the immune 
balance in a negative way. Although viruses trigger the process related to the autism, the 
basic devastating factor is the cytokines that are activated following the infection. In autism, 
inflammatory agents are generally related to the astrocytes and microglial cell activation. 
The existence of chronic microglial activation is indicated on the brains of autistic 
individuals. In autism, there is an increase in the proinflammatory chemokines and 
modulator cytokines (Cohly and Panja 2005). Detected increase in the level of 
proinflammatory cytokines such as IL – 6, TNF – alpha and monocyte chemoatractan 
protein 1 (MCP – 1) in the brain samples and cerebrospinal fluid indicates that active neural 
inflammatory process is continuing in autism (Careaga et al. 2010). TNF- alpha is a strong 
immunomodulatory cytokine that is produced by macrophages and partly by active T cells. 
As well as its important function in the development of brain, it may have a role in the 
arrangement of glutamatergic transmission. It is put forward that TNF – alpha levels may be 
the indicator of possible inflammatory damage in autistic disorder (Chez et al. 2007). In the 
study performed by Jyonouchi and his collegues (2001) an increase in the serum of TNF – 
alpha, IL-1β and IL-6 levels in autistic individuals is indicated and the existence of improper 
hereditary immune response in autism is mentioned. However, there is various study 
results in which no change is observed in the levels of serum of TNF – alpha in autistic 
disorder (Güney et al. 2008). In different study, increased serum IL – 12 and IFN – gamma 
levels are determined and no significant change is reported on IFN-alpha, IL-6, TNF-alpha 
serum levels (Singh 1996). It is indicated that there is a decline occur on anti – inflammatory 
cytokine levels such as IL – 10 and transforming growth factor beta (TGF-β) on autistic 
individuals. However, in all studies made in this field no consistent results in terms of 
cytokine patterns could be provided (Careaga et al. 2010).  
Studies in which an increase on autoantibody unique to the brain is indicated support the 
autoimmune mechanism. In the serum of autistic individuals, autoantibodies against the 
proteins (myelin basic protein, neuron axon, filament protein, glial fibrillary acidic protein) 
limited by nervous system are observed (Schmitz and Rezaie 2008). In a study carried out by 
Singh and Rivas (2004), antibodies are determined against caudat nucleus (49%) cerebral 
cortex (18%) and cerebellum (9%). It is put forward that these autoantibodies lead to 
symptoms observed in autism by corrupting neurological functions. Furthermore 
autoantibodies against receptor of serotonin are observed on autistic individuals (Singh et 
al. 1997). 
In particular for HLA (human leukocyte antigen) gens, it is thought that many gens have 
relation with risk increase in the formation of certain autoimmune diseases. Different HLA 
haplotypes are also associated with neural developmental disorders like autism. Many HLA 
haplotype especially HLA – DR 4 is more frequently observed on autistic children than the 
general society. HLA genes are within a large genomic region called MHC (major histo - 
compatibility complex). This region includes a vast of genes. One of these genes is the 
complement protein C4 gene which is important for natural immunity (Careaga et al. 2010). 
The relation of complement 4B null allele with autism related to various autoimmune 
diseases was examined by Mostafa and Shehab (2010). It is indicated that in Egyptian 
children C4B null allele frequency is significantly higher. The relation of other gens such as 
macrophage migration inhibitor factor (MIF) gen and serine and threonine kinase C gen, 
PRKCB with autism is indicated (Careaga et al. 2010).  
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In many studies, a meaningful relation between familial autoimmunity and autism is found. 
It is associated with autistic characteristics such as the existence of the familial history of 
allergic/ autoimmune disease, regression and such as increased head circumference (Croen 
et al 2005, Molloy et al. 2006, Sacco et al. 2007). It is indicated that in the family of autistic 
individuals the number of autoimmune disease is much more (Comi et al. 1999). When 
family members with autoimmune disease goes up from 1 to 3, autism risk will increase and 
probability ratio goes up from 1.9 to 5.5. The most common autoimmune diseases in these 
families are diabetes mellitus type 1, adult rheumatoid arthritis, hypothyroidism, celiac 
disease and systemic lupus erythematous. Yet in a study performed by Croen and his 
collegues (2005) the relation between the existence of autoimmune disease in mother (auto-
immune diseased mother) and autism was supported. It is claimed that rather than a 
specific disorder in mother, a general immune function disorder will have relation with the 
increase in autism risk. (Careaga et al. 2010).  
The fact that autoantibodies against the critical neural components of fetal brain structure of 
some mothers of autistic children is detected, shows the possible potential mechanism in the 
form of transmissing the antibodies to the fetus developing in pregnancy of the mother. It is 
thought that anti – fetal brain autoantibodies that are available nearly on 12 % of the 
mothers of autistic children are connected to the neuronal targets during the formation and 
therefore they affect the neuronal formation. The view stating that antibodies isolated from 
the mother by animal models may affect the neural formation in the early period and 
therefore it may lead to behavioral changes (Careaga et al. 2010). 
In line with the studies made in order to understand the neurobiology of autism, it is 
indicated that immunological factors also play a role in the etiopathogenesis of the disorder. 
Various findings such as the existence of antibodies against neural antigens and 
autoimmune disease history in the family support the possible role of immunological factors 
in autism. Although so far achieved symptoms make contribution to data that are related to 
the neurobiology of autism, they don’t affect the diagnosis and treatment of autism. In the 
future, it is aimed to use these data in the separation of autism from other 
neurodevelopmental disorders and during the diagnosis and treatment process.  
2. Neurotrophic factors  
Several lines of evidence suggest that cytokines, growth factors and neurotrophic factors 
play particular signaling roles with in the brain to produce neurochemical, 
neuroendocrinological and behavioral changes (Hashimoto et al. 2003). Neurotrophic factors 
play an important role in the development of peripheral and central nervous system. 
Neurotrophic factors have an important function in the neurodevelopmental process for 
survival and differentiation of neurons, and regulation of their functions. Last findings 
showed us that the pathophysiology of autism is associated with neurotrophic factors. It is 
suggested that in some of the abnormality of neurotrophic factors may be implicated in 
mechanism associated with neural dysfunction in autism (Nelson et al 2006, Suzuki et al. 
2007, Toyoda et al. 2007). 
Neurotrophic factors comprise a range of different protein superfamilies. The well-known 
group among neurothrophic factors are neurotrophins. Nerve growth factor (NGF), brain-
derived growth factor (BDNF), neurotrophin (NT)-3, NT-4, NT-5 ve NT-6 are members of 
neurotrophin family. Other than the neurotrophins, neurotrophic superfamilies contain too 
many protein families such as neurokines (for example ciliary NTF (CNTF) and leukaemia 
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inhibitory factor (LIF) ), insulin-like growth factors (for example, IGF-1 and IGF-2), 
fibroblast growth factors (for example FGF-1, FGF-2), as well as transforming growth factor-
β (TGF-β) super family and epidermal growth factor superfamily (Barde 1990, Götz et al. 
1994, Barbacid 1995, Nickl-Jockschat and Michel 2011). 
The most important member of neurotrophin family having too many functions such as 
neuronal survival, target innervations and synaptogenesis in development of peripheral and 
central nerveus system is BDNF. All the neurotrophins bind with lower affinity to the p75 
receptor and with high affinity to receptors of the tyrosine kinase family: NGF binds to 
TrkA, BDNF and NT-4 bind TrkB, NT-3 binds to TrkC (McKay et al. 1999). Neurotrophins 
perform their biological functions through such receptors. In neuron differentiation process, 
BDNF has too many roles such as neuronal survival, activity-dependent dendritic and 
axonal outhgrowth/branching, synapse formation and neuronal plasticity (reviewed in 
Polleux and Lauder 2004, Shieh ve Ghosh 1997). In various studies, the relationship 
of BDNF gene with autism is examined. Nishimura and his collegues (2007) determined 
increase of BDNF expression in autistic individuals. In different studies that followed, the 
probable role of BDNF gene mutation in autism pathogenesis is supported (Cheng et al. 
2009). In a recent study by which significant increase of BDNF serum levels are determined 
in terms of autistic children, it is found that genetic variations of BDNF gene has no 
significant effect on risk of autism. However, a significant relationship is reported between 
neurotrophic thyrosine kinase, receptor, type 2=NTRK2 and autism (Correira et al. 2010).  
In various studies, it is examined, whether there is any difference in the level of 
neurotrophic factor in serum and cerebrospinal fluid (CSF) of autistic children or not. In a 
study performed by Nelson and his collegues (2001), neonatal blood levels of neurotrophic 
factors are examined in autistic children and non autistic children with mental retardation. 
When compared with control group, in both groups, an important increase was observed in 
BDNF and neurotrophin 4/5 neonatal blood levels. In autism and a heterogenic group with 
cognitive functional defect, this result is very important in terms of indicating some 
neurotrophins’ excessive express in peripheral blood taken in the early days of the life. 
However it is unknown whether these substances are also at high levels in prenatal life or 
not, or how long they remain at high levels in postnatal period. In their comprehensive 
study, Nelson and his collegues determined when compared with control group, that there 
is significant increase serum neurotrophin -4 and BDNF (the two TrkB ligands) in autism 
spectrum disorders and mental retardation without autism, but there were no changes with 
respect to NGF (trkA ligands) and neurotrophin-3 (TrkC ligands) levels. In line with these 
findings, it is suggested that trkB ligands are expressed or secreted at higher levels in the 
central nerveus system of children having autism or mental retardation during early infancy 
(reviewed in Polleux and Lauder 2004). It is suggested that the effect of BDNF and 
nörotrofin-4 on activity dependent dendritic outgrowth and branching (McAllister et al 
1996, 1997), is related to the early and transient brain growth observed in autistic babies 
(Courchesne et al. 2003, reviewed in Polleux and Lauder 2004).  
This increased level of BDNF expression and/or secretion is thought to have a relationship 
with the role of Methyl-CpG-binding protein 2 (MeCP2) in the control of BDNF 
transcription (Chen et al. 2003) Mutation in MeCP2 gene is responsible for Rett Syndrome. It 
is shown that MeCP2 binds selectively to BDNF promoter III and performs the function of 
repressing the expression of BDNF gene (Shahbazian et al. 2002). The MeCP2 gene 
mutations, by having effect on BDNF expression and potentially dendritic differentiation in 
cortex, may become a risk factor for autism (reviewed in Polleux and Lauder 2004). For that 
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purpose, in a study by which MeCP2 gene mutation in autistic individuals is researched, de 
novo mutation is found in two girls (Carney et al. 2003). 
In a different study on children with autism spectrum disorders, the existence of 
autoantibodies against BDNF in the serum is shown together with the increase on the level 
of BDNF, and it is put forward that there is an interaction between BDNF and immune 
system (Connolly and et al. 2006). Morrison and Mason (1998) reported that the levels of 
increased BDNF and neurotrophin-4 resulted in the decline in the purkinje cell number in 
the existence of granular cells. Although it is suggested that changes in the levels of 
neurotrophin on autistic individuals may be the primary factor in the formation of autism, it 
is still not certain whether these changes are primary etiopathagenic mechanism or 
secondary reaction against cortical changes (Pardo ve Eberhart 2007).  
By taking the changes determined in serum BDNF levels in autism spectrum disorders, 
Croen and his colleagues (2008) studied the usability of BDNF as an early biological marker 
for autism. In their evaluation of BDNF concentrations in mid-pregnancy and neonatal 
blood specimens, they found no differences between subjects with autism compared with 
subjects with mental retardation or with general population controls. It is reported that in 
critical period of early development, concentration of BDNF would not be a useful clinic 
biomarker for autism (Croen et al. 2008). 
In a different study, the age-related changes of serum BDNF levels were studied and it was 
indicated that there were disturbances of BDNF level trajectories in autism cases. In healthy 
controls, the serum BDNF concentration was found to be increased over the first several 
years and decreased slightly after reaching the adult level. In the autism cases, mean levels 
were significantly lower in children between 0-9 ages compared to teenagers or adults, or to 
age-matched healthy controls, indicating a delayed BDNF increase with development. In the 
same study, circadian changes, but not seasonal changes, were found in serum levels of 
BDNF (Katoh-Semba et al. 2007). 
There is a little number of studies that concentrated on CSF levels of neurotrophic factors. 
Riikonen and Vanhala (1999) investigated CSF NGF levels in children with infantile autism 
and children with Rett syndrome. It was indicated that mainly normal CSF NGF levels were 
found in autism, whereas there were low to negligible values in Rett Syndrome. 
TGF-β signaling, is related with too many biological processes that cover cell growth, 
differentiation and morphogenesis. By keeping in mind the key role of TGF-β in mental 
development and in controlling immune responses, it was hyphothesized that TGF-β1 could 
have a relationship with pathophysiology of autism. In various studies regarding autistic 
children and adults, it was determined that when compared with control group, the serum 
TNF-β1 levels were significantly lower in the autistic patients (Okada et al.2007, Ashwood et 
al. 2008). It is suggested that this finding is in relationship with abnormalities in mental 
development and immune process regulation, which have been observed in autistic 
patients.  
IGFs are peptides that regulate growth and differentiation as well as being synthesized in 
most tissues including the developing central nervous system (Bach and Rechler 1995, Jones 
and Clemmons 1995). It was shown that IGF 1 levels in CSF of autistic children were lower 
and this might play a role in the pathogenesis of autism (Vanhala et al. 2001). Because IGF 1 
is important for the survival of Purkinje cells of the cerebellum, it is put forward that low 
concentrations of CSF IGF1 at an early stage might be linked with the pathogenesis in 
autism (Riikonen et al. 2006).  
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EGF is a member of growth factors which play an important role in the cellular proliferation 
and the differentiation of the central and peripheral nervous system (Wong and Guillaud 
2004). EGF has been suggested to be involved especially in the growth and survival of 
midbrain dopaminergic neurons (Alexi and Hefti 1993; Casper et al. 1991; Casper and Blum 
1995). The most effective drugs in autism treatment are antipsychotics which block dopamin 
receptors; according to these findings it’s suggested that there might be dopaminergic 
hyperactivity in autism pathophysiology. In a recent study, considering the role of EGF in 
mental development, it’s relation with pathophysiology of autism was investigated and it 
was demonstrated that levels of EGF were significantly lower in adults with high 
functioning autism (Suzuki et al. 2007). Contrary to this finding, in a different study carried 
out on a pediatric autistic group, serum EGF levels in children with autism were 
significantly higher than those of age-matched normal healthy control subjects. This 
difference determined among and between adult and pediatric age groups in terms of 
serum EGF levels might be associated with possible developmental abnormality in the 
regulation of EGF expression. It can be expected that EGF levels may increase in early ages 
and begin to decrease as the autistic individual gets older (Işeri et al. 2011).  
Due to the fact that behavioral symptoms and functional impairment degree are variable, 
autism is defined as the heterogeneous symptom cluster that has different etiology and 
pathology. Although phenotypic heterogeneity is the biggest obstacle in front of the 
research carried out that are oriented to defining the etiology of the autism, the fact that 
research techniques related to the biological factors are increased in the recent period and 
that research made on such field has become widespread, is promising. Due to their key 
roles during the neurodevelopment, neurotrophic factors have become one of the issues 
focused on research carried out that are oriented to determining the etiopathogenesis of 
autism. In most of the studies, significant differences were detected on the levels of serum 
neurotrophic factor. Studies performed up to now showed that neurotrophic factors could 
play a role in the pathophysiology of autism. However, it is necessary to integrate the 
findings of those studies above with new studies investigating the anatomical and 
functional changes on central nervous system of autistic patients in the future.  
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